US Stock Market Move | Bambusa Therapeutics (BBTX.US) debuts on the U.S. stock market, shares fall over 8%.

On Friday, Bambusa Therapeutics (BBTX.US) debuted on the U.S. stock market. As of press time, the stock fell over 8% to $14.685. The IPO price was $16. Bambusa Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, USA, focused on developing next-generation long-acting bispecific antibody drugs for the treatment of immune system and inflammatory diseases. These drugs can simultaneously target two disease-related biological targets, aiming to improve therapeutic efficacy, extend duration of action, and reduce patient dosing frequency. The company's lead investigational drug BBT001 is for the treatment of atopic dermatitis (eczema), chronic spontaneous urticaria, and other skin diseases; another candidate drug BBT002 primarily targets inflammatory diseases such as asthma, chronic obstructive pulmonary disease, and chronic rhinosinusitis with nasal polyps. In addition, the company is developing early-stage drugs for inflammatory bowel disease and autoimmune diseases.